Virus-like particles (VLPs) hold great promise for the development of effective and affordable vaccines. VLPs, indeed, are suitable for presentation and efficient delivery to antigen-presenting cells of linear as well as conformational antigens. This will ultimately result in a crosspresentation with both MHC class I and II molecules to prime CD4+ T-helper and CD8+ cytotoxic T cells. This review describes an update on the development and use of VLPs as vaccine approaches for HIV.
- baculovirus expression vector system
- broadly neutralizing antibody
- conformational antigen presentation
- insect cells stable expression
ASJC Scopus subject areas
- Drug Discovery
- Molecular Medicine